- This event has passed.
QB3 Webinar: Sonja Schrepfer, Sana Biotechnology. “The Future of Stem Cell Therapy: Hypoimmune Cell Products”
September 15 @ 1:00 pm - 2:00 pm
Induced pluripotent stem cells (iPSCs) hold great potential as therapies to repair damaged tissue or replace cell types missing due to genetic defects. However, even iPSCs derived from a patient can mutate in culture, causing immune rejection when they are re-transplanted. Being able to control immune rejection is key to using iPSCs as theraputics. The end goal, for safety and efficiency, is a gene-engineered, hypoimmunogenic, universal cell product. In this talk, Sonja Schrepfer of Sana Biotechnologies will describe how she and Sana are working to ensure that transplanted iPSCs survive both T cell and innate immune surveillance.